{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-002920","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2025-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.134895+00:00","generated_at":"2026-05-28T08:56:23.100818+00:00","sec_items":["3.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sensei Biotherapeutics gets bid-price extension to July 7, 2025; transfers to Nasdaq Capital Market","bullets":["Nasdaq approved transfer to Capital Market; trading under SNSE starts Jan 8, 2025.","Received additional 180-day period until July 7, 2025 to regain $1 minimum bid compliance.","If not compliant by July 7, Nasdaq will issue delisting notice; company may appeal but no guarantee.","Evaluating options including reverse stock split to address bid price deficiency."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-002920","json":"https://secwatch.observer/filing/0001193125-25-002920.json","markdown":"https://secwatch.observer/filing/0001193125-25-002920.md","text":"https://secwatch.observer/filing/0001193125-25-002920.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312525002920/0001193125-25-002920-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312525002920/d909848d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T08:56:23.100818+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d11ac5b147ae66aac9baf1b96fc30a9c3b3456d8","claim":"Sensei Biotherapeutics, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).","evidence_excerpt":"January 7, 2025 (the “Second Nasdaq Notice”), that the Company’s application to transfer to the Nasdaq Capital Market was approved and the Company is eligible for an additional 180 calendar day period, or until July 7, 2025 (the “Second Compliance Date”), to regain compliance with the minimum bid price requirement. At the opening of business on January 8, 2025, the Company’s common stock will be transferred to the Nasdaq Capital Market, which operates in substantially the same manner as the Nasdaq Global Select Market, where it continues to trade under the symbol “SNSE”. The Company intends to","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312525002920/0001193125-25-002920-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"extension granted"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5450(a)(1), 5810(c)(3)(A)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}